Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: A phase II study

Michele Orditura; Gennaro Galizia; Vincenzo Napolitano; Erika Martinelli; Roberto Pacelli; Eva Lieto; Gaetano Aurilio; Loredana Vecchione; Floriana Morgillo; Giuseppe Catalano; Fortunato Ciardiello; Alberto Del Genio; Natale Di Martino; Ferdinando De Vita

doi:10.3109/07357901003630926

Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: A phase II study

Michele Orditura, Gennaro Galizia, Vincenzo Napolitano, Erika Martinelli, Roberto Pacelli, Eva Lieto, Gaetano Aurilio, Loredana Vecchione, Floriana Morgillo, Giuseppe Catalano, Fortunato Ciardiello, Alberto Del Genio, Natale Di Martino, Ferdinando De Vita

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with radiotherapy (46 Gy) as primary treatment in locally advanced esophageal cancer (LAEC). The main end point was the activity in terms of pathologic complete response (pathCR) rate. Thirty-three LAEC patients received chemoradiation therapy during weeks 1-6 followed by esophagectomy. A pathCR was observed in 10/33 patients; 20/33 and 3/33 patients showed PR and SD, respectively. The EUS maximal transverse cross sectional area reduction >50 significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen.

Original language	English
Pages (from-to)	820-827
Number of pages	8
Journal	Cancer Investigation
Volume	28
Issue number	8
DOIs	https://doi.org/10.3109/07357901003630926
Publication status	Published - Sep 2010

Keywords

Cisplatin
Esophageal cancer
Paclitaxel
Preoperative chemoradiotherapy

ASJC Scopus subject areas

Cancer Research
Oncology
Medicine(all)

Access to Document

10.3109/07357901003630926

Cite this

Orditura, M., Galizia, G., Napolitano, V., Martinelli, E., Pacelli, R., Lieto, E., Aurilio, G., Vecchione, L., Morgillo, F., Catalano, G., Ciardiello, F., Genio, A. D., Martino, N. D., & De Vita, F. (2010). Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: A phase II study. Cancer Investigation, 28(8), 820-827. https://doi.org/10.3109/07357901003630926

Orditura, M, Galizia, G, Napolitano, V, Martinelli, E, Pacelli, R, Lieto, E, Aurilio, G, Vecchione, L, Morgillo, F, Catalano, G, Ciardiello, F, Genio, AD, Martino, ND & De Vita, F 2010, 'Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: A phase II study', Cancer Investigation, vol. 28, no. 8, pp. 820-827. https://doi.org/10.3109/07357901003630926

@article{70ad6c63873148a38e142f2944a86752,

title = "Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: A phase II study",

abstract = "We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with radiotherapy (46 Gy) as primary treatment in locally advanced esophageal cancer (LAEC). The main end point was the activity in terms of pathologic complete response (pathCR) rate. Thirty-three LAEC patients received chemoradiation therapy during weeks 1-6 followed by esophagectomy. A pathCR was observed in 10/33 patients; 20/33 and 3/33 patients showed PR and SD, respectively. The EUS maximal transverse cross sectional area reduction >50 significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen.",

keywords = "Cisplatin, Esophageal cancer, Paclitaxel, Preoperative chemoradiotherapy",

author = "Michele Orditura and Gennaro Galizia and Vincenzo Napolitano and Erika Martinelli and Roberto Pacelli and Eva Lieto and Gaetano Aurilio and Loredana Vecchione and Floriana Morgillo and Giuseppe Catalano and Fortunato Ciardiello and Genio, {Alberto Del} and Martino, {Natale Di} and {De Vita}, Ferdinando",

year = "2010",

month = sep,

doi = "10.3109/07357901003630926",

language = "English",

volume = "28",

pages = "820--827",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "8",

}

TY - JOUR

T1 - Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer

T2 - A phase II study

AU - Orditura, Michele

AU - Galizia, Gennaro

AU - Napolitano, Vincenzo

AU - Martinelli, Erika

AU - Pacelli, Roberto

AU - Lieto, Eva

AU - Aurilio, Gaetano

AU - Vecchione, Loredana

AU - Morgillo, Floriana

AU - Catalano, Giuseppe

AU - Ciardiello, Fortunato

AU - Genio, Alberto Del

AU - Martino, Natale Di

AU - De Vita, Ferdinando

PY - 2010/9

Y1 - 2010/9

N2 - We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with radiotherapy (46 Gy) as primary treatment in locally advanced esophageal cancer (LAEC). The main end point was the activity in terms of pathologic complete response (pathCR) rate. Thirty-three LAEC patients received chemoradiation therapy during weeks 1-6 followed by esophagectomy. A pathCR was observed in 10/33 patients; 20/33 and 3/33 patients showed PR and SD, respectively. The EUS maximal transverse cross sectional area reduction >50 significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen.

AB - We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with radiotherapy (46 Gy) as primary treatment in locally advanced esophageal cancer (LAEC). The main end point was the activity in terms of pathologic complete response (pathCR) rate. Thirty-three LAEC patients received chemoradiation therapy during weeks 1-6 followed by esophagectomy. A pathCR was observed in 10/33 patients; 20/33 and 3/33 patients showed PR and SD, respectively. The EUS maximal transverse cross sectional area reduction >50 significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen.

KW - Cisplatin

KW - Esophageal cancer

KW - Paclitaxel

KW - Preoperative chemoradiotherapy

UR - http://www.scopus.com/inward/record.url?scp=77956636233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956636233&partnerID=8YFLogxK

U2 - 10.3109/07357901003630926

DO - 10.3109/07357901003630926

M3 - Article

C2 - 20482249

AN - SCOPUS:77956636233

VL - 28

SP - 820

EP - 827

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 8

ER -

Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: A phase II study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this